ALNYLAM PHARMACEUTICALS ($ALNY) posted quarterly earnings results for Q4 2025 on Thursday, February 12th. The company reported earnings of $1.25 per share, beating estimates of $1.19 by $0.06. The company also reported revenue of $1,097,030,000, missing estimates of $1,196,261,100 by $-99,231,100.
You can see Quiver Quantitative's $ALNY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALNYLAM PHARMACEUTICALS Insider Trading Activity
ALNYLAM PHARMACEUTICALS insiders have traded $ALNY stock on the open market 287 times in the past 6 months. Of those trades, 0 have been purchases and 287 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:
- YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 61 sales selling 51,130 shares for an estimated $22,285,590.
- DENNIS A AUSIELLO has made 0 purchases and 11 sales selling 31,448 shares for an estimated $13,729,535.
- KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 58 sales selling 19,765 shares for an estimated $8,616,191.
- COLLEEN F REITAN has made 0 purchases and 16 sales selling 18,000 shares for an estimated $8,416,729.
- MICHAEL W BONNEY sold 11,250 shares for an estimated $5,062,500
- PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 52 sales selling 10,320 shares for an estimated $4,539,736.
- JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 41 sales selling 8,875 shares for an estimated $3,766,776.
- TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 47 sales selling 7,785 shares for an estimated $3,373,461.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALNYLAM PHARMACEUTICALS Hedge Fund Activity
We have seen 451 institutional investors add shares of ALNYLAM PHARMACEUTICALS stock to their portfolio, and 382 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 2,107,295 shares (-49.2%) from their portfolio in Q3 2025, for an estimated $960,926,520
- REGENERON PHARMACEUTICALS, INC. removed 1,392,303 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $553,649,287
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,344,712 shares (-42.8%) from their portfolio in Q3 2025, for an estimated $613,188,672
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,185,909 shares (+698.8%) to their portfolio in Q3 2025, for an estimated $540,774,504
- WINSLOW CAPITAL MANAGEMENT, LLC removed 1,176,104 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $536,303,424
- FMR LLC added 961,104 shares (+6.1%) to their portfolio in Q3 2025, for an estimated $438,263,424
- JANE STREET GROUP, LLC added 935,894 shares (+4094.7%) to their portfolio in Q3 2025, for an estimated $426,767,664
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALNYLAM PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 01/30/2026
- Barclays issued a "Overweight" rating on 01/28/2026
- Needham issued a "Buy" rating on 01/12/2026
- Truist Securities issued a "Buy" rating on 01/08/2026
- Stifel issued a "Buy" rating on 12/11/2025
- Piper Sandler issued a "Overweight" rating on 10/31/2025
- Jefferies issued a "Buy" rating on 10/30/2025
To track analyst ratings and price targets for ALNYLAM PHARMACEUTICALS, check out Quiver Quantitative's $ALNY forecast page.
ALNYLAM PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ALNY recently. We have seen 18 analysts offer price targets for $ALNY in the last 6 months, with a median target of $509.0.
Here are some recent targets:
- Michael Ulz from Morgan Stanley set a target price of $408.0 on 01/30/2026
- Tazeen Ahmad from B of A Securities set a target price of $462.0 on 01/30/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $510.0 on 01/30/2026
- Eliana Merle from Barclays set a target price of $527.0 on 01/28/2026
- Luca Issi from RBC Capital set a target price of $465.0 on 01/20/2026
- Derek Archila from Wells Fargo set a target price of $376.0 on 01/20/2026
- Joseph Stringer from Needham set a target price of $529.0 on 01/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
